Massa A, Mousel M, Durfee C, Herndon M, Hemmerling K, Taylor J
Animals (Basel). 2021; 11(7).
PMID: 34206933
PMC: 8300134.
DOI: 10.3390/ani11071907.
Ntakpe J, Gabillard D, Moh R, Gardiennet E, Emieme A, Badje A
EBioMedicine. 2020; 56:102815.
PMID: 32512517
PMC: 7276518.
DOI: 10.1016/j.ebiom.2020.102815.
Pasternak A, Grijsen M, Wit F, Bakker M, Jurriaans S, Prins J
JCI Insight. 2020; 5(6).
PMID: 32097124
PMC: 7213790.
DOI: 10.1172/jci.insight.134196.
Rouzioux C, Avettand-Fenoel V
Retrovirology. 2018; 15(1):30.
PMID: 29615133
PMC: 5883363.
DOI: 10.1186/s12977-018-0412-7.
Avettand-Fenoel V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A
Clin Microbiol Rev. 2016; 29(4):859-80.
PMID: 27559075
PMC: 5010749.
DOI: 10.1128/CMR.00015-16.
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption.
Hurst J, Hoffmann M, Pace M, Williams J, Thornhill J, Hamlyn E
Nat Commun. 2015; 6:8495.
PMID: 26449164
PMC: 4633715.
DOI: 10.1038/ncomms9495.
HIV-1 DNA predicts disease progression and post-treatment virological control.
Williams J, Hurst J, Stohr W, Robinson N, Brown H, Fisher M
Elife. 2014; 3:e03821.
PMID: 25217531
PMC: 4199415.
DOI: 10.7554/eLife.03821.
Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.
Beck I, Jang M, Mckernan-Mullin J, Bull M, Wagner T, Huang S
AIDS Res Hum Retroviruses. 2011; 28(8):780-8.
PMID: 22081867
PMC: 3399556.
DOI: 10.1089/AID.2011.0039.
Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe.
Demetriou V, van de Vijver D, Kousiappa I, Balotta C, Clotet B, Grossman Z
PLoS One. 2010; 5(6):e10976.
PMID: 20544014
PMC: 2882320.
DOI: 10.1371/journal.pone.0010976.
Development and assessment of a multiplex real-time PCR assay for quantification of human immunodeficiency virus type 1 DNA.
Beloukas A, Paraskevis D, Haida C, Sypsa V, Hatzakis A
J Clin Microbiol. 2009; 47(7):2194-9.
PMID: 19420173
PMC: 2708521.
DOI: 10.1128/JCM.01264-08.
Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.
Kassaye S, Johnston E, McColgan B, Kantor R, Zijenah L, Katzenstein D
J Acquir Immune Defic Syndr. 2009; 50(1):9-18.
PMID: 19295330
PMC: 2818215.
DOI: 10.1097/QAI.0b013e31818ffdff.
Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.
Sahu G, Paar D, Frost S, Smith M, Weaver S, Cloyd M
J Med Virol. 2008; 81(1):9-15.
PMID: 19031450
PMC: 2912142.
DOI: 10.1002/jmv.21366.
Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.
Sarmati L, Parisi S, Nicastri E, DEttorre G, Palmisano L, Andreotti M
J Clin Microbiol. 2005; 43(12):6183-5.
PMID: 16333125
PMC: 1317166.
DOI: 10.1128/JCM.43.12.6183-6185.2005.
Viral load responses to HAART is an independent predictor of a new AIDS event in late stage HIV infected patients: prospective cohort study.
Kazanjian P, Wei W, Brown M, Gandhi T, Amin K
J Transl Med. 2005; 3:40.
PMID: 16262894
PMC: 1298340.
DOI: 10.1186/1479-5876-3-40.
Different patterns of HIV-1 DNA after therapy discontinuation.
Re M, Vitone F, Sighinolfi L, Schiavone P, Ghinelli F, Gibellini D
BMC Infect Dis. 2005; 5:69.
PMID: 16156892
PMC: 1236926.
DOI: 10.1186/1471-2334-5-69.